Comparison of hepatic resection and systemic treatment of breast cancer liver metastases: A propensity score matching study

Am J Surg. 2020 Oct;220(4):945-951. doi: 10.1016/j.amjsurg.2020.02.047. Epub 2020 Feb 28.

Abstract

Background: The role of surgery in breast cancer liver metastases (BCLM) remains elusive, and current application is limited. Our aim is to investigate whether hepatic resection (HR) of BCLM improves survival compared with non-hepatic resection (NHR) treatment.

Methods: Three hundred and eighty-four patients with BCLM from 2008 to 2018 were divided into two groups. Propensity score matching (PSM) analysis was used to compare the clinical outcomes.

Results: After PSM the mean overall survival (OS) and the 1, 3, and 5-year OS rates in HR group were 61.8 months, 92.6%, 54.7% and 54.7%, respectively; while for NHR group these values were 38.6 months, 79.2%, 45.6% and 21.9%, respectively (p < 0.007). Multivariate analysis indicated hormonal receptor status (p = 0.039) and hepatic resection (p = 0.032) were independent prognostic factors.

Conclusion: Our study revealed that hepatectomy yields a survival benefit safely compared with medical treatments, especially for patients with positive hormonal receptors.

Keywords: Breast cancer liver metastases; Hepatic resection; Prognosis; Propensity score matching study.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms / diagnosis
  • Breast Neoplasms / mortality
  • Breast Neoplasms / therapy*
  • China / epidemiology
  • Combined Modality Therapy / methods
  • Female
  • Hepatectomy / methods*
  • Humans
  • Liver Neoplasms / mortality
  • Liver Neoplasms / secondary
  • Liver Neoplasms / therapy*
  • Middle Aged
  • Propensity Score*
  • Survival Rate / trends
  • Treatment Outcome